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Abstract Vitamin D exerts its canonical roles on the muscu-
loskeletal system and in the calcium/phosphorus homeostasis.
In the last years, increasing evidences suggested several extra-
skeletal actions of this hormone, indicating that vitamin D
may produce effects in almost all the body tissues. These are
mediated by the presence of vitamin D receptor (VDR) and
thanks to the presence of the 1-α-hydroxylase, the protein that
converts the 25-hydroxyvitamin (calcidiol) to the active form
1,25-dihydroxyvitamin (calcitriol). Several studies evaluated
the possible role of vitamin D in the pathogenesis of thyroid
diseases, and this reviewwill focus on the available data of the
literature evaluating the association between vitamin D and
thyroid function, vitamin D and autoimmune thyroid diseases,
including Hashimoto’s thyroiditis, Graves’ disease and post-
partum thyroiditis, and vitamin D and thyroid cancer.
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1 Introduction
The term ‘vitamin D’ generally indicates two different com-
pounds, the cholecalciferol (or vitamin D3) and the
ergocalciferol (vitamin D2). Vitamin D3 is normally
synthetized in the skin upon exposure to ultraviolet B
(UVB) radiation by the action of the 7-dehydrocholesterol
reductase. In addition, it can be introduced with the diet from
few dietary sources (i.e. fatty fish). Ergocalciferol represents
the dietary source of vitamin D and it is synthesized by plants
and fungi. Both forms are transferred to the liver, were they
are hydroxylated to 25-hydroxyvitamin D (25-OH-D3, or
calcidiol). This is the major circulating and storage form of
vitamin D [1]. Evaluation of serum 25-(OH)-D3 is considered
to provide a reliable evaluation of the vitamin D status [2].
The vitamin D active form is produced by the 1-α-
hydroxylase protein. This protein, encoded by the CYP27B1
gene and expressed mainly in the kidney, determines the hy-
droxylation of calcidiol to 1,25-(OH)2D3 (calcitriol).
Calcitriol formation is down-regulated via a negative feedback
by calcitriol concentrations and by the fibroblast growth factor
23 (FGF23). Calctriol is inactivated by the action of the 24-
hydroxylase.
The active form of vitamin D binds nuclear vitamin D
receptor (VDR) and heterodimerizes with retinoic acid. This
complex interacts with vitamin D responsive elements of tar-
get genes to exert its effects. Also, a form of a membrane-
bound vitamin D receptor has been hypothesized, which
would mediate non-genomic, rapid effects of calcitriol [3].
Several polymorphic variants of the genes involved in me-
tabolism, transport, and activity of vitamin D have been de-
scribed in the last years. The best characterized are the four
single-nucleotide polymorphic (SNP) variants of the VDR
gene (ApaI, BsmI, FokI, and TaqI) that have been associated
with several pathological situations, including autoimmune
disorders or cancers [4, 5].
Other genes, whose variants may lead to altered availability
and metabolism of vitamin D are: DHCR7, GC, CYP2R1,
CYP27B1, CYP24A1. These genes encode for proteins
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mentioned above: 7-dehydrocholesterol reductase, vitamin D
binding protein (DBP), 25-hydroxylase, 1-alpha-hydroxylase,
and 24-hydroxylase, respectively.
In the last years, the idea that Vitamin D is an hormone that
acts not only on the skeletal system but on a great number of
target tissues has been supported by the identification of the
VDR in nearly all tissue types [6], including the thyroid gland
[1, 7].
Herein the relationships between vitamin D and thyroid
diseases have been reviewed. The manuscript is based on an
electronic literature search of PubMed database performed in
September and October 2016. The selection of the articles was
done using the subsequent search terms in association with
vitamin D: Hashimoto’s thyroiditis; Graves’ disease; Post-
partum thyroiditis; thyroid cancer.
2 Vitamin D and thyroid status
Thyroid hormones (thyroxine or T4 and triiodothyronine or
T3, TH) are vital for the control of metabolism and for main-
taining specific function of several tissue and cell types.
Biosynthesis of TH occurs within the thyroid gland and it is
stimulated by the thyroid-stimulating hormone (TSH) secreted
by the pituitary. Data on the direct interactions between
Vitamin D and circulating TH or TSH are very poor.
Experiments with rodents demonstrated that in rats the ad-
ministration of calcitriol (0.05 microgram/kg per day for
3 days) did not change TSH or T4 [8]. By contrast, rats fed
with a severely vitamin D deficient diet had lower serum TSH
but T4 levels similar to vitamin D sufficient animals [9]. In
addition, VDR knock out mice had no alterations in morphol-
ogy and function of the thyroid gland and showed only a slight
reduction in circulating TSH levels [10].
In healthy humans, no clear data are available on the effects
of vitamin D status (excess or deficiency) on thyroid function.
In a cohort of hospitalized patients without history of thy-
roid disease, no differences were observed in basal serum
TSH between patients with a very low (≤10 ng/mL) or high
(≥40 ng/mL) vitamin D status [11]. Other reports indicate
contrasting results. Chailurkit and coworkers studied a Thai
cohort and demonstrated that high vitamin D status is associ-
ated with low circulating thyrotropin [12] only in young,
while Zang and others reported a similar association also in
elderly [13].
Mackawy et al. suggested that hypothyroidism is associat-
ed to low vitamin D levels with a negative correlation between
TSH and calcidiol [14]. In contrast, Bouillon and coworkers
found that vitamin D levels had no differences between hypo-
thyroid or hyperthyroid patients and healthy subjects [15].
Finally, no effects of hyperthyroidism on circulating Vitamin
D levels have also been reported by both Jastrup and
Macfarlane [16, 17].
3 Vitamin D and autoimmune thyroid disorders
Several studies indicated that vitamin D plays a significant
role in the modulation of the immune system [18, 19].
Immune cells express both VDR and the 1-a-hydroxylase
which is responsible for 25-hydroxyvitamin D activation.
Indeed, vitamin D has important effects on both monocytes
and dendritic cells (DC) including inhibition of inflammatory
cytokines (interleukin (IL)-1, IL-6, IL-8, IL-12 and tumor
necrosis factor (TNF)-α) in monocyte and reduction of
Major Histocompatibility Complex (MHC) class II molecules
expression. Moreover, vitamin D also determines suppres-
sion of T cell proliferation [20], whose final effect is a reduc-
tion in the number of antigen-presenting cells. Globally, vita-
min D may enhance the innate immune system and regulate
the adaptive immune system, promoting immune tolerance
and acting to decrease the likelihood of developing auto-
immune disease [18].
Autoimmune thyroid diseases (AITD) are the most fre-
quent autoimmune disorders, and the most common patholog-
ical conditions of the thyroid gland occurring in approximate-
ly 5% of the population [21, 22]. The AITD comprise two
main clinical presentations: Graves’ disease (GD) and
Hashimoto’s thyroiditis (HT). Both forms are characterized
by lymphocytic infiltration of the thyroid parenchyma, but
while GD is clinically characterized by hyperthyroidism,
ophthalmopathy and pretibial myxedema [23], the clinical
hallmarks of HT is the hypothyroidism, determined by lym-
phocytic destruction of the thyroid gland [24].
As the majority of autoimmune disorders, AITDs is the
consequence of a complex interaction between genetic sus-
ceptibility factors (i.e. thyroid-specific and immunoregulatory
genes), existential factors (sex, parity, etc.), and various envi-
ronmental triggers (i.e. cigarette smoking, stress, iodine, sele-
nium, etc.) [25].
The role of both vitamin D and VDR in the pathogenesis of
AITD have largely been investigated in the last years. Vitamin
D receptor is expressed in lymphocytes, macrophages as well
as in antigen presenting cells [26]. The innate immune system
is activated in presence of Vitamin D, while the acquired im-
mune response is inhibited. Moreover, associations between
autoimmune disease and reduction of Vitamin D circulating
levels have recently been reviewed [20]. With a specific focus
on autoimmune thyroid disorders, several observations have
been published in both animal models and in human studies.
3.1 Animal models
Mice previously sensitized with porcine thyroglobulin have
been intraperitoneal injected with or without calcitriol (0.1–
0.2 micrograms per kg body weight daily) by Fournier and
coworkers. Animals receiving these suboptimal doses of vita-
min D presented a reduction in the severity thyroid
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inflammation compared to placebo treated mice [27]. The ef-
fects were even higher when mice were treated with both
calcitriol and cyclosporine [28].
Liu and coworkers pretreated mice with intraperitoneal in-
jection of calcitriol (5 micrograms per kg every 48 h) before
performing sensitization with porcine thyroglobulin. Contrary
to what observed in the placebo group, the thyroid not showed
the typical inflammation signs, suggesting a protective role of
vitamin D in prevention of thyroiditis [29].
Effects of vitamin D in GD animal models have been stud-
ied by Misharin et al. [30]. BALB/c mice have been produced
as model of GD by immunization with adenovirus encoding
the A-subunit of thyrotropin receptor. Compared with mice
fed regular chow, hyperthyroid BALB/mice fed with a vitamin
D deprived diet showed fewer splenic B cells, decreased
interferon-gamma responses to mitogen and lack of memory
T-cell responses to A-subunit protein, but no differences in
TSHR antibody levels have been observed. Moreover, vita-
min D-deficient BALB/c mice had lower preimmunization T4
levels and developed persistent hyperthyroidism suggesting
that vitamin D directly modulates thyroid function in this an-
imal model [30].
3.2 Human studies
In the last years, several studies have investigated the circulat-
ing vitamin D levels in patients with AITD. A weak connec-
tion between low vitamin D levels and AITDs was identified
in a study conducted in a population from India [31], while no
correlation between vitamin D and Ab-Tg antibodies was
demonstrated in Thai subjects [12].
By contrast, Kivity et al. observed that anti-thyroid anti-
bodies were more frequently elevated in patients with vitamin
D deficiency [32]. The same study, however, indicates that the
prevalence of vitamin D deficiency was similar between hy-
pothyroid patients with AITDs or without AITD (72% vs
52%, p = 0.08), not allowing to exclude that vitamin D defi-
ciency is determined by hypothyroidism and not a primary
phenomenon involved in AITD pathogenesis.
Tamer et al. demonstrated that patients with HT had lower
vitamin D levels when compared to age- and sex-matched
controls. Moreover, vitamin D insufficiency (<30 ng/mL) oc-
curred more frequently in patients with HT rather than in a
healthy population [33]. Nevertheless, the authors were not
able to demonstrate a significant difference among the degree
of vitamin D insufficiency between hypothyroid, euthyroid or
hyperthyroid patients with HT, suggesting that vitamin D
levels do not correlate with the progress of damage to
thyrocyte. In contrast, a potential role of vitamin D in the
development or progression of HT has been suggested by
Bozkurt et al., demonstrating a correlation between severity
of vitamin D deficiency and duration of HT, antibody levels
and thyroid volume [34].
The association between AITD and calcidiol was also in-
vestigated by Choi and coworkers in a large cross-sectional
study, involving about 6700 participants. The authors demon-
strated that the levels of serum vitamin D were significantly
lower in pre-menopausal, but not in post-menopausal women
with AITD [35].
Shin et al. reported that patients with elevated anti-thyroid
antibodies had significantly lower levels of serum 25(OH)D3
when compared to normal subjects. Moreover, after adjusting
for age, sex, and body mass index, a negative correlation
(r = −0.252, p < 0.001) was recognized between 25(OH)D3
and TPOAb levels in the AITDs patients [36].
By comparing newly diagnosed AITD patients with
healthy age-matched controls, Unal et al. demonstrated that
both HT and GD patients had lower circulating 25-OH-D3
compared to controls [37].
The relationships between vitamin D levels and HT in chil-
dren have been investigated by Camurdan et al. The authors
observed lower vitamin D levels and higher prevalence of
vitamin D deficiency in children with new diagnosis of HT
compared to sex- and age-matched controls [38]. Relation
between vitamin D and AITD in young was recently studied
also in a cohort of 56 Egyptian children with AITD and 56
healthy controls [39]. Also this report indicates that vitamin D
deficiency is more frequent in the AITD group compared to
the control subjects, and a significant negative correlations can
be demonstrated between serum 25-OH vitamin D and age,
duration of the disease, BMI, anti-TPO and anti-Tg antibodies
and TSH. On the basis of these observations, the authors sup-
posed that the vitamin D level is not an independent risk for
the progression of AITD to overt hypothyroidism [39].
Sönmezgöz et al. confirmed these results in a group of 136
Turkish children. The prevalence of vitamin D deficiency was
higher (76%) in HT patients than in the control group (35%).
All hypothyroid HT patients also had a vitamin D deficiency
[40]. Similar results have also been reported by Evliyaoğlu,
who measured serum 25-OH vitamin D3 levels in 169 sub-
jects, demonstrating that levels lower than 20 ng/mL were
associated to HT in children and adolescents [41].
The relationships between vitamin D and GD have been
less investigated. Kivity et al. reported significantly higher
prevalence of vitamin D deficiency in GD patients than in
healthy individuals matched by age (64% vs 30% respective-
ly, p < 0.01) [32]. Newly identified GD female patients were
studied for vitamin D levels by Yasuda et al. in 2012. The
authors reported a decrease in the circulating vitamin D levels
in GD patients and demonstrated a significant association of
vitamin D deficiency with thyroid volume, but not with TRAb
levels or thyroid function [42]. The same authors also found
lower vitamin D levels in female GD patients without remis-
sion than in those with remission [42].
All the data on the associations between vitamin D and GD
have been reviewed in a recent meta-analysis by Xu and
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coworkers. In this report, the authors conclude that low vita-
min D status may increase the risk of Graves’ disease, how-
ever pathogenetic mechanisms related to this association still
remains unclear, and it has not yet been clarified if supplement
of vitamin D may have beneficial effect in GD [43].
To date, several authors have studied the association be-
tween functional polymorphism in the VDR gene and AITD
risk. The VDR is the specific vitamin D receptor and its ac-
tivity can be compromised by certain polymorphisms. The
first meta-analysis performed to assess the association be-
tween the alleles of vitamin D receptor gene polymorphisms
and Graves’ disease was performed by Zhou and coworkers in
2008. The authors concluded that ApaI, BsmI and FokI
polymorphisms of the VDR gene were associated with sus-
ceptibility to GD in Asian populations, while ApaI, BsmI,
TaqI and FokI polymorphisms were not associated with GD
in Caucasian populations [44]. In 2013, Feng and coworkers
performed a meta-analysis demonstrating a relevant link be-
tween VDR polymorphism and autoimmune thyroiditis [45].
The results indicated that the BsmI (rs1544410) or TaqI
(rs731236) polymorphisms were significantly associated with
AITD risk, while ApaI (rs7975232) or FokI (rs2228570) poly-
morphisms were not. Later, it has been demonstrated that the
frequency of allele TT for the TaqI was higher in GD patients
rather than in HT patients, while the frequency of the C allele
for the ApaI was higher in GD patients than in normal controls
[46]. Meng et al. [47] also demonstrated a higher frequency of
allele A in ApaI in GD patients compared to controls, but no
significant difference were found in BsmI, FokI and TaqI
polymorphisms.
In conclusion, despite the number of papers studying the
associations between vitamin D and AITD is constantly in-
creasing, data are still not conclusive. There are suggestions
indicating that vitamin D deficiency may be a condition asso-
ciated with a higher risk of developing AITD, but it is still
unclear whether this has a specific role in the pathogenesis of
the diseases or is a consequence of the disease. Moreover, it
has not been defined if vitamin D supplementation may mod-
ulate the evolution or the treatments of AITD.
4 Vitamin D and post-partum thyroiditis
Postpartum thyroiditis is a form of subacute thyroiditis that
normally occurs within 6–12 months after delivery. The prev-
alence of postpartum thyroiditis ranges from 1.1 to 16.7% of
all pregnancies, with an overall incidence of 7.5% [48]. As
most of the subacute thyroiditis the clinical course is charac-
terized by a thyrotoxic phase occurring 1–3 months after par-
turition, followed by hypothyroidism at 3–6 months after de-
livery [49]. Finally, normal thyroid function is usually
achieved within a year, however about 25% of women with
a history of PPT will develop permanent hypothyroidism in
the ensuing 10 years [50].
Several papers have recently analyzed the association be-
tween circulating levels of vitamin D and postpartum thyroid-
itis (PPT).
Krysiak and coworkers investigated the levels of 25-
hydroxyvitamin D and parathyroid hormone in four groups
of non-lactating women who gave birth within 12 months
before the beginning of the study: group A was composed
by hypothyroid women with post-partum thyroiditis
(n = 14), group B by euthyroid females with post-partum thy-
roiditis (n = 14); group C by women with non-autoimmune
hypothyroidism (n = 16) and group D by healthy euthyroid
females (n = 15). Serum levels of 25-hydroxyvitamin D were
lower and PTH levels were higher in patients with post-
partum thyroiditis than in patients without thyroid autoimmu-
nity. L-thyroxine treatment increased 25-hydroxyvitamin D
and reduced PTH levels only in hypothyroid women with
post-partum thyroiditis. The results suggested an association
between vitamin D status and post-partum thyroiditis, despite
the authors had to admit several limitations of the study [51].
More recently, the same group has studied 38 non-lactating
L-thyroxine-treated women with postpartum thyroiditis (PPT)
and 21 matched healthy postpartum women. 25-hydroxy vi-
tamin D levels were lower in women with PPT than in healthy
women, and anti-TPO and anti-Tg antibody titers inversely
correlated with vitamin D status. The authors noted that vita-
min D supplementation was able to reduce titers of thyroid
peroxidase and suggested that vitamin D supplementation
may bring benefits to L-thyroxine-treated women with PPT
[52]. This work, however, received strong critics in a letter in
the same issue of the journal [53] and data on the role of
vitamin D in PPT, in our view, are still incomplete and very
controversial.
5 Vitamin D and thyroid cancer
In addition to its main role in calcium homeostasis, vitamin D
has been associated with risk for several types of cancer, prob-
ably in consequence of its effects on cell proliferation, differ-
entiation, apoptosis, and anti-angiogenesis [54, 55]. Several
studies suggest that vitamin D may play a role in the patho-
genesis, progression, and therapy for cancer. It has been sug-
gested that lower serum vitamin D levels can be associated
with higher risk of cancers. In this view, suboptimal vitamin D
concentrations in serum have been proposed as an important
cancer risk factor for several types of tumors, including thy-
roid cancers [3, 56].
To date, very limited data are available on the clinical sig-
nificance of vitamin D supplementation as measure to reduce
the risk of cancer. Many in vitro and animal studies indicate
that high concentrations vitamin can reduce the progression of
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cell cycle, may induces apoptosis and slow neoplastic cell
growth. Moreover, vitamin D has been also demonstrated to
potentiates the antitumor activity of various anticancer drugs,
however the mechanisms that underlie the antitumor activities
of vitamin D are still unclear. In view additional studies are
required in order to better define the role of vitamin D in
cancer, and this is true also for thyroid cancers [57]. Here,
the effects of vitamin D potential role in thyroid cancers will
be reviewed, considering the in vitro, in vivo and human avail-
able data.
5.1 In vitro evidences
The vitamin D activity is mediated by binding to VDR, which
is expressed in both normal and malignant epithelial thyroid
cells. Both VDR and 1-α-hydroxylase were found to be in-
creased in papillary thyroid carcinoma (PTC) compared with
normal thyroid tissue [58]. Moreover, VDR expression was
reduced in metastatic lymph nodes of PTC compared with
both normal thyroid tissue and primary PTC, suggesting that
vitamin D pathway may be associated with differentiation and
reduced proliferation in PTC [58]. Additional in vitro studies
demonstrated that 25(OH)D3 was able to decrease prolifera-
tive activity of follicular thyroid cells [59] and modulate ex-
pression of ECM protein-1 (ECM1) and the type II transmem-
brane serine protease-4 (TMPRSS4), two independent predic-
tor of thyroid carcinoma [60]. Indeed, RT-PCR experiments
revealed a higher mRNA expression of ECM1, TMPRSS4
and VDR in the malignant thyroid tissues compared to the
normal thyroid tissues from the same patients. ECM1 has been
detected in numerous malignant epithelial tumors, while
TMPRSS4 is a protein involved in invasion, metastasis, mi-
gration, adhesion, and epithelial-mesenchymal transition in
cancer cells. Therefore, the association between VDR to
ECM1 and TMPRSS4, suggested a potential role of VDR in
thyroid carcinoma [60].
The study by Clickspoor and coworkers demonstrated an
increased expression of VDR, CYP24A1 and CYP27B1
genes, all key players involved in local vitamin D signaling,
in benign and differentiated malignant thyroid tumors. A de-
crease in these genes expression was observed in local nodal
and distant metastasis, suggesting a local antitumor response
to vitamin D in early cancer stages [61].
The function of vitamin D in cancer has been also validated
with synthesis of vitamin D analogs, such as MART-10. It has
been demonstrated that MART-10 is more potent than
1α,25(OH)2D3 to repress cancer growth and metastasis in
undifferentiated thyroid cancer cells. These results require fur-
ther investigations and in vivo study to use MART-10 as po-
tent drug to inhibit anaplastic thyroid cancer cell metastatic
potential [62].
Finally, very recently, the effects of calcitriol have been
investigated also in a model of thyro-spheres of cell derived
from anaplastic carcinomas. The results indicated that
calcitriol inhibited proliferation of the anaplastic thyroid car-
cinoma cells with a more pronounced effect on doxorubicin-
resistant cells. Moreover, it reduced the capacity to form stem
cell-derived spheres and decreased the size of these spheres,
indicating that, also in this model, vitamin D exert a pro-
differentiation effect [63].
5.2 Animal models
Dackiw and coworkers implanted in the neck of 4- to 5-
weeks-old female SCID mice human thyroid follicular carci-
noma derived (WRO). Animals were treated with i.p. injection
of 0.75 microg/kg calcitriol or vehicle for 21 day. Average
tumor volume presented a 38% reduction (P < 0.003) in ani-
mals treated with vitamin D. Moreover, tumors excised from
calcitriol-treated animals demonstrated signs of differentiation
with restoration of thyroglobulin staining not observed in
vehicle-treated mice. The results suggested that calcitriol ad-
ministration can restore p27 accumulation in thyroid carcino-
ma cells, reducing tumor size and preventing metastatic
growth [59]. The results reported by Liu et al. were in the same
direction were, demonstrating that calcitriol treatment was
able to determine a 50% reduction of tumor weight and a
22% reduction of tumor volume in mice xenografted with
tumor cancer cells [64].
5.3 Human studies
The antiproliferative effects of vitamin D have been well char-
acterized in vitro and in vivo using animal models, and a pro-
tective role of vitamin D for non-cutaneous cancer has also
been proposed [65]. However, clinical data are still not suffi-
cient to determine whether low circulating vitamin D can be
considered a risk factor for cancers, and it is not yet possible to
draw definitive conclusions on the effect of vitamin D supple-
mentation on cancer risk [66]. This is true especially for thy-
roid cancer.
Several reports indicate no significant differences compar-
ing vitamin D levels between cancer patients and healthy con-
trols. In 2010, Laney and coworkers evaluated serum calcium,
creatinine, albumin, and 25-hydroxy vitamin D (25-OH-D) in
patients with thyroid nodule (42), thyroid cancer in remission
(45), and active thyroid cancer (24) and found that serum 25-
OH-D was not different between groups. Multivariate regres-
sion analysis showed that only a BMI of ≥30 kg/m2 can be a
good predictor of vitamin D deficiency [67]. No difference in
concentrations of 25(OH)D3 between patients with papillary
thyroid cancer and patients with HT have been observed by
Lizis-Kolus et al. Moreover, in this study, no relationship has
been demonstrated between serum 25(OH)D3 and clinical
stage of the disease or TSH level in patients with papillary
thyroid carcinoma [68]. Also Jonklaas and coworkers
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demonstrated no associations between vitamin D concentra-
tion and thyroid cancer. In addition, serum vitamin D concen-
trations were not associated with disease stage or other prog-
nostic features [69]. Very recently, Ahn and coworkers evalu-
ated a large group of patients (820) with papillary thyroid
cancer. Among those, 795 had insufficient vitamin D levels
(<30 ng/mL), however serum vitamin D levels were not asso-
ciated with disease aggressiveness and poor outcomes [70].
Finally, indirect evidences suggesting no association between
vitamin D and thyroid cancers were provided by O’Grady
et al. In their report the authors investigated the dietary intake
of several micronutrients and were able to establish a relation-
ship only between thyroid cancer and low vitamin C intake,
but not with other micronutrients, including vitamin D [71].
Contrasting data suggesting an association between serum
vitamin D levels and thyroid cancer have been reported by
other groups.
Roskies et al. performed a retrospective cohort study on
212 patients undergoing thyroidectomy. Preoperative 25-
hydroxyvitamin D(3) levels were recorded and patients were
stratified based on vitamin D status as vitamin D deficiency
(VDD) or vitamin D sufficiency (VDS). The comparison of
malignancy prevalence between VDD (75%) and VDS
(37.5%) indicate a relative risk of 2.0 (p = .03, 95% CI 1.07-
2.66) associated to vitamin D deficiency, suggesting that vita-
min D may be a modifiable risk factor for thyroid cancer [72].
Similarly, Sahin et al. demonstrated the presence of low serum
vitamin D (calcidiol < 20 ng/mL) in 71% of patients with pap-
illary thyroid carcinomas, but only in 59% of controls [73].
Kim et al. studied a total of 548 female patients who
underwent total thyroidectomy for PTC. Patients were catego-
rized into four quartiles according to the preoperative serum
25(OH) vitamin D levels, and clinicopathologic features of
PTC were analyzed. The results indicated that lower preoper-
ative serum 25(OH) vitamin D levels appear to be associated
with poor clinicopathologic features in female patients with
PTC [74].
6 Conclusion
The majority of the data here reported suggest that vitamin D
insufficiency or deficiency may be associated with increased
risk of thyroid autoimmunity and that reduced serum concen-
trations of vitamin D are linkedwith a major aggressiveness of
thyroid cancers. It has to be noted, however, that data are still
inconclusive and many papers present contradictory results.
Several racial differences have been reported in the scientific
literature that may suggest that vitamin D metabolism has also
differences linked to ethnicity, which can, at least in part,
explain the observed differences.
It is likely that, in order to better understand the role of
vitamin D in thyroid disease, several and more extensive
prospective studies need to be performed. In addition, in thy-
roid cancer, it will be necessary to perform long-term supple-
mentation studied to evaluate if higher concentrations of vita-
min D may influence the patient outcome.
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